Patient Case Studies and Panel Discussion: Leukemia and Myeloproliferative Neoplasms
Although advances in treatment options for patients with hematologic malignancies are encouraging, the rapidly changing scientific and clinical environment represents a daunting challenge for practitioners.
Category
  • Leukemia
  • Myeloproliferative Neoplasms
Format
  • Recorded Webcast
Credits
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Optimizing TKI Therapy for Chronic Phase CML: Sequencing of TKI Therapy and Treatment-free Remission
The availability of multiple tyrosine kinase inhibitors (TKIs) for the treatment of newly diagnosed chronic phase chronic myeloid leukemia (CML) poses significant challenges to the clinicians in terms of selection of initial TKI therapy and sequencing TKI therapy in patients with intolerance to t
Category
  • Chronic Myelogenous Leukemia
Format
  • Recorded Webcast
Credits
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Prognostic Significance of Mutations in Myeloproliferative Neoplasms
The diagnosis and management of patients with myeloproliferative neoplasms (MPN) has evolved since the identification of “driver” mutations (JAK2, CALR, and MPL mutations).
Category
  • Myeloproliferative Neoplasms
Format
  • Recorded Webcast
Credits
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Patient Case Studies and Panel Discussion: Plasma Cell Neoplasms
Although advances in treatment options for patients with hematologic malignancies are encouraging, the rapidly changing scientific and clinical environment represents a daunting challenge for practitioners.
Category
  • Multiple Myeloma
Format
  • Recorded Webcast
Credits
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Current Approaches to Initial Treatment of Newly Diagnosed Multiple Myeloma
The number of treatment options for both transplant eligible and transplant ineligible patients continues to grow year after year.  Regimens previously approved in the second-line setting are proving to be efficacious as primary therapy.
Category
  • Multiple Myeloma
Format
  • Recorded Webcast
Credits
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Emerging Options and Sequencing Therapies for Relapsed Multiple Myeloma
Promising clinical responses have even been seen in heavily pretreated patients, suggesting that the new therapeutic options benefit those who have exhausted all traditional lines of therapy.
Category
  • Multiple Myeloma
Format
  • Recorded Webcast
Credits
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Management of Bone Health in Patients with Hematologic Malignancies
Many patients with hematologic malignancies are at risk for treatment-induced bone loss which in turn can result in pathologic fractures, hypercalcemia, bone pain, and decline in motility and performance status.
Category
  • Hematologic Malignancies
Format
  • Recorded Webcast
Credits
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Optimizing the Care of Patients Receiving CAR T-Cell Therapy
Patients with relapsed or refractory hematologic disorders like acute lymphoblastic leukemia and diffuse large B-cell lymphoma have poor outcomes and require novel effective therapies.
Category
  • Acute Lymphoblastic Leukemia
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • ANCC contact hours
  • Participation
Management of Toxicities Associated with Immune Checkpoint Inhibitors
Nurses play a critical role in the recognition and management of immune-related adverse events (irAEs).
Category
  • Hematologic Malignancies
Format
  • Recorded Webcast
Credits
  • ANCC contact hours
  • Participation
Strategies to Identify Needs and Coordinate Referrals to a Multidisciplinary Chronic Graft-Versus-Host Disease Clinic
Chronic graft-versus-host disease (GVHD) is a potentially serious complication that significantly impacts quality of life in patients undergoing allogeneic hematopoietic cell transplant.  Treatment of chronic GVHD can be optimized by providing coordinated care involving a multidisciplinary team p
Category
  • Hematologic Malignancies
Format
  • Recorded Webcast
Credits
  • ANCC contact hours
  • Participation

Pages